Jump to content

Platelet transfusion refractoriness

From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by TransfusionDoctor (talk | contribs) at 03:03, 28 December 2018 (Improved definition). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Platelet transfusion refractoriness is the repeated failure to achieve the desired level of blood platelets in a patient following a platelet transfusion. The cause of refractoriness may be either immune or nonimmune based. Among immune-related refractoriness, antibodies against HLA antigens are the primary cause. Non-immune causes include splenomegaly (enlargement of the spleen), fever, and sepsis.[1][2]

Cause

Platelet refractoriness can be due to immune causes or non-immune causes.[3] Non-immune causes account for over 80% of cases of platelet refractoriness, and sepsis is one of the most common non-immune causes.[2][3][4] HLA alloimmunization is the commonest immune cause of platelet refractoriness.[2][3][4]

Non-immune causes

  • Fever
  • Treatment of infection, antibiotics (vancomycin), antifungals (amphotericin B)
  • Bleeding

Immune causes

  • Other antibodies
    • Drug-related antibodies

Diagnosis

Platelet transfusion refractoriness is typically diagnosed using the corrected count increment, which requires 4 items of information:[citation needed]

  1. Pre-transfusion platelet count
  2. Post-transfusion platelet count: the post-transfusion blood sample for this measurement should be collected 10–60 minutes after the transfusion has been completed
  3. Body surface area
  4. Number of platelets transfused: the blood bank maintains records of the estimated number of platelets in each unit. Current requirements in the US stipulate that a unit of apheresis platelets must contain at least 3.0 x1011 platelets.[5]

The CCI is calculated as follows: CCI= (Post-transfusion platelet count - Pre-transfusion platelet count)(BSA) ÷ (number of platelets transfused).

A CCI greater than 7500 indicates a sufficient post-transfusion increment, whereas a CCI less than 7500 is considered diagnostic of platelet refractoriness.[citation needed]

Immune-mediated refractoriness usually shows little or no increment in the immediate post-transfusion platelet count. Non-immune refractoriness may show an initial rise in platelet count, but a subsequent 8-hour or 12-hour post-transfusion sample shows a return to the baseline platelet count.[citation needed]

References

  1. ^ Colman, Robert W.; Marder, Victor J.; Clowes, Alexander W.; George, James N.; Goldhaber, Samuel Z. (2005), Hemostasis and Thrombosis: Basic Principles and Clinical Practice (5th ed.), Lippincott Williams & Wilkins, p. 1195, ISBN 0-7817-4996-4
  2. ^ a b c Stanworth, Simon J.; Navarrete, Cristina; Estcourt, Lise; Marsh, Judith (2015). "Platelet refractoriness – practical approaches and ongoing dilemmas in patient management". British Journal of Haematology. 171 (3): 297–305. doi:10.1111/bjh.13597. ISSN 1365-2141.
  3. ^ a b c "Guidelines for the management of platelet transfusion refractoriness" (PDF). hospital.blood.co.uk. Retrieved 2018-12-28. {{cite web}}: Cite has empty unknown parameter: |dead-url= (help)
  4. ^ a b "transfusion.com.au". transfusion.com.au. Retrieved 2018-12-28.
  5. ^ AABB (2014). Standards for Blood Banks and Transfusion Services. AABB. ISBN 9781563958878.